


Discover Life Science Canada

by JETRO Canada and Shonan iPark

 #3 Hamilton EcoSystem

日時 日本時間
9am-10am on 3/19 (Friday)
EST
8pm-9pm on 3/18 (Thursday)

会場 Web EX

 Meeting number (access code)
131 236 4036
Meeting password
k2GgPPaE@68

[CLICK HERE to join the webinar](#)

Agenda

1. Opening Remarks
2. Overview of Hamilton Life Science Ecosystem
Synapse Life Science Consortium
3. Startup Pitch
Triumvira Immunologics / Adapsyn / Synmedix
4. Q&A

MC

- Tyson Garbe, Associate Director, JETRO Toronto
- Yuri Ogiso, Commercial and Business Development, Shonan iPark

Overview of Hamilton Life Science Ecosystem



 **Presenter**
Alex Muggah
Director
Synapse Life Science Consortium



Hamilton, one of Canada's leading health research and educational clusters, is a launchpad for innovative life science research and commercialization. At the nexus of Ontario's dynamic \$52 billion health care industry, Hamilton possesses an unmatched network of research-intensive hospitals, leading academic institutions, globally recognized researchers and clinicians, and private-sector companies. More than 35,000 professionals work together to develop and deploy health innovations that are changing lives around the world. Hamilton is anchored by the Canadian HQ of global medical device companies (Stryker), the most comprehensive hospital network in Ontario and one of Canada's leading research hospitals (Hamilton Health Sciences) and Canada's most research-intensive academic institution and the home of evidence-based medicine (McMaster University). The Hamilton community is eager to collaborate around the next generation of innovation, and build on our foundation of success, such as the second largest biotech IPO in Canadian history.

<https://synapseconsortium.com/>



Startup Pitch

  **Presenter**
Jonathan Bramson
scientific co-founder,
acting Chief Scientific Officer



Triumvira Immunologics, Inc. ("Triumvira") is a clinical stage immunotherapy company with the vision of developing novel T-cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T-cell receptor (TCR) therapies. Our proprietary T-cell Antigen Coupler (TAC) technology recruits the entire natural T-cell receptor and functions independent of the Major Histocompatibility Complex (MHC), potentially allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are in Austin, Texas, with our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com



<https://triumvira.com/>

  **Presenter**
Chris Dejong
Vice President of Technology



Adapsyn Overview: Adapsyn Bioscience is a chemical bioinformatics company that discovers and develops novel small molecule therapeutics. Adapsyn's platform analyses metabolomic and genomic data from bacteria to identify, isolate, characterize, and assay novel drug-like molecules, and we have established the capability to screen thousands of compounds per year. We can identify gene clusters that encode small molecules that target specific enzymes, and we can evaluate a molecule's potential to be developed as a therapeutic based on our analysis of the gene cluster alone. The technology can be applied to find new drugs in the fields of oncology; bacterial, fungal and viral infection; autoimmune disorders; cardiovascular and lipid metabolism disorders; neuroscience; and others. In 2016, Adapsyn established a partnership with Pfizer Inc., and completed an initial financing in 2017 that was co-led by Genesys Capital and Pfizer Ventures.

<https://adapsyn.com/>

  **Presenter**
Eric Brown
CEO



Synmedix is a start-up, biotechnology company created to commercialize a novel and propriety antibiotic platform to address the unmet medical need posed by the global health crisis in antibiotic resistance. Discovered in the Brown Laboratory at McMaster University, Synmedix technology dramatically enhances the effectiveness of antibiotics through the action of bicarbonate. The bicarbonate platform enhances both the efficacy and spectrum of many antibiotics and is broadly applicable to antibacterial drug discovery and development. The technology has unique potential to transform the treatment of polymicrobial, chronic wound infections.